請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39336
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林欽塘(Chin-Tarng Lin) | |
dc.contributor.author | Jia-Hung Ye | en |
dc.contributor.author | 葉家宏 | zh_TW |
dc.date.accessioned | 2021-06-13T17:26:16Z | - |
dc.date.available | 2005-02-03 | |
dc.date.copyright | 2005-02-03 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-01-19 | |
dc.identifier.citation | 1. Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol. 1999 Sep; 37(9):2899-903.
2. Abrass CK, Berfield AK, Andress DL. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am J Physiol. 1997 Dec; 273(6 Pt 2):F899-906. 3. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res. 2003 Nov-Dec; 35(11-12):726-33. 4. Al-Shahrour F D-UR, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. 2003. 5. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G, Marvaldi J, Luis J. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer. 1999 Nov 12; 83(4):497-505. 6. Andress DL, Loop SM, Zapf J, Kiefer MC. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem Biophys Res Commun. 1993 Aug 31; 195(1):25-30. 7. Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998; 13:179-87. 8. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 2001 Jun;54(3):145-8. 9. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000; 24:1465-79. 10. Bellin T, Pulz M, Matussek A, Hempen HG, Gunzer F. Rapid detection of enterohemorrhagic Escherichia coli by real-time PCR with fluorescent hybridization probes. J Clin Microbiol. 2001 Jan; 39(1):370-4. 11. Berfield AK, Andress DL, Abrass CK. IGFBP-5(201-218) stimulates Cdc42GAP aggregation and filopodia formationin migrating mesangial cells. Kidney Int. 2000 May; 57(5):1991-2003. 12. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases : evolution, structure and function. Biochim Biophys Acta. 2000 Mar 7; 1477(1-2): 267-83. 13. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995 Oct 19; 377(6550):646-9. 14. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000 Dec 15; 275(50):39174-81. 15. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003 Nov; 253(1-2):269-85. 16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563-6. 17. Chen W, Martinez G, Mulchandani A. Molecular beacons: a real-time polymerase chain reaction assay for detecting Salmonella. Anal Biochem. 2000 Apr 10; 280(1):166-72. 18. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17:353-60. 19. Cohen P, Lamson G, Okajima T, Rosenfeld RG. Transfection of the human IGFBP-3 gene into Balb/c fibroblasts: a model for the cellular functions of IGFBPs. Growth Regul. 1993 Mar; 3(1):23-6. 20. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988; 263:6579-87. 21. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol. 1998 Feb; 20(1):157-62. 22. Conover CA, Bale LK, Durham SK, Powell DR. Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology. 2000 Sep; 141(9):3098-103. 23. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999; 17:799-808. 24. Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate. 2002 May 1; 51(2):141-52. 25. Drop SL, Schuller AG, Lindenbergh-Kortleve DJ, Groffen C, Brinkman A, Zwarthoff EC. Structural aspects of the IGFBP family. Growth Regul. 1992 Jun; 2(2):69-79. 26. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74. 27. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824-54. 28. Formigli L, Fiorelli G, Benvenuti S, Tani A, Orlandini GE, Brandi ML, Zecchi-Orlandini S. Insulin-like growth factor-I stimulates in vitro migration of preosteoclasts across bone endothelial cells. Cell Tissue Res. 1997 Apr; 288(1):101-10. 29. Galiano RD, Zhao LL, Clemmons DR, Roth SI, Lin X, Mustoe TA. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model. J Clin Invest. 1996 Dec 1; 98(11):2462-8. 30. Goodman MT, Correa CN, Tung KH, Roffers SD, Cheng Wu X, Young JL, Jr.. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer 2003; 97:2648-59. 31. Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R, Ghigo E. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J. 2004 Sep; 18(12):1456-8. Epub 2004 Jul 09. 32. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of the type 1 IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 2004; 202:50-9. 33. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996 Apr 1; 56(7):1545-50. 34. Guo S, Kemphues KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995 May 19; 81(4):611-20. 35. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998 Jan 23; 279(5350):509-14. 36. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6. 37. Hannon GJ, Conklin DS. RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol Biol. 2004; 257:255-66. 38. Health Department. Part 1 General Health Statistics. In Health and Vital statistics. Taiwan, ROC. 2001. p. 87. 39. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987; 38:137-47. 40. Hidalgo M, Eckhardt SG. Matrix metalloproteinase inhibitors: how can we optimize their development? Ann Oncol. 2001 Mar;12(3):285-7. 41. Hochscheid R, Jaques G, Wegmann B. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol. 2000 Sep; 166(3):553-63. 42. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately Up-Regulated Genes in Ovarian Cancer. Cancer Res 2001; 61:3869-76. 43. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 2003 Jul 10; 424(6945):219-23. 44. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 1996 Jan 12; 271(2):1016-21. 45. Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD, Rees C, Clemmons DR. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest. 1997 Nov 15; 100(10):2596-605. 46. Iwata Y, Wada T, Furuichi K, Sakai N, Matsushima K, Yokoyama H, Kobayashi K. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol. 2003 Jan; 14(1):57-67. 47. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res. 2002; 84:57-80. 48. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol. 2002 Jan 21; 156(2):299-313. Epub 2002 Jan 14. 49. Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol. 2004 Jun; 24(12):5565-76. 50. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998; 58:1707-12. 51. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002 Dec 6; 298(5600):1911-2. 52. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A. 1993 Nov 15; 90(22):10553-7. 53. Juan HF, Lin JY, Chang WH, Wu CY, Pan TL, Tseng MJ. Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatic analytical methods. Electrophoresis 2002; 23:2490-504. 54. Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001; 37:478-85. 55. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 2004 Mar 15; 64(6):2229-37. 56. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 1996 Aug; 137(8):3206-12. 57. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 2002 Jun 15; 62(12):3530-7. 58. Leng SL, Leeding KS, Whitehead RH, Bach LA. Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol. 2001 Mar 28; 174(1-2):121-7. 59. Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993; 68: 716-27. 60. Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 1990; 62:713-24. 61. MacDonald RG, Schaffer BS, Kang IJ, Hong SM, Kim EJ, Park JH. Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3. J Gastroenterol Hepatol. 1999 Jan; 14(1):72-8. 62. Martell M, Gomez J, Esteban JI, Sauleda S, Quer J, Cabot B, Esteban R, Guardia J. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol. 1999 Feb; 37(2):327-32. 63. Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS, Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000; 6:750-65. 64. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri MA, Clemmons DR. Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: the modulating effect of cell released IGF binding proteins (IGFBPs). J Cell Physiol. 1990 Aug;144(2):244-53. 65. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23:40-7. 66. Mira E, Manes S, Lacalle RA, Marquez G, Martinez AC. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999; 140:1657-64. 67. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-4. 68. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Demonstration of receptors for insulin- like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993; 268:26045-8 69. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 1993 Jul 15; 268(20):14964-71. 70. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem. 1995 Jun 9; 270(23):13589-92. 71. Ohwada M, Suzuki M, Suzuki T, Hiratsuka M, Kawai T, Saito K. Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer 2001; 93:376-80. 72. Oliver DH, Thompson RE, Griffin CA, Eshleman JR. Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis. J Mol Diagn. 2000 Nov; 2(4):202-8. 73. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999 Aug; 20(4):535-82. 74. Portera CA Jr, Shinohara H, Mima T, Miller A, Tsan R, Mascarenhas D, Radinsky R. Targeting the insulin-like growth factor axis in the therapy of colorectal carcinoma liver metastasis. Growth Horm IGF Res. 2000 Apr; 10 Suppl A:S47-8. 75. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995; 6:273-84. 76. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997 May 2; 272(18):12181-8. 77. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49-54. 78. Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol. 1998 Oct; 13(4):865-9. 79. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7:2396-404. 80. Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG. Gene Expression in Ovarian Cancer Reflects Both Morphology and Biological Behavior, Distinguishing Clear Cell from Other Poor-Prognosis Ovarian Carcinomas. Cancer Res 2002; 62:4722-9. 81. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J. Genetic Analysis of Early- versus Late-Stage Ovarian Tumors. Cancer Res 2001; 61:5895-904. 82. Simpson JL, Bischoff FZ. Heritability and molecular genetic studies of endometriosis. Ann N Y Acad Sci 2002; 955:239-51. 83. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004 Oct; 165(4):1087-95. 84. Torng PL, Mao TL, Chan WY, Huang SC, Lin CT. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004; 92:559-67. 85. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000 May 5; 288(5467):870-4. 86. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000 Apr; 293(1):281-8. 87. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995; 9:361-7. 88. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr, Davis RJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev. 2004 Nov 15 89. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 2003 Jul; 4(1):67-79. 90. Vu, T.H., and Werb, Z. Matrix metalloproteinases, effectors of development and normal physiology. Genes Dev. 2000; 14, 2123-2133. 91. Webb CP, Van Aelst L, Wigler MH, Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8773-8. 92. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246-52. 93. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. PNAS 2001; 98:1176-81. 94. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997 Nov 14; 91(4):439-42. 95. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999 Jan 4; 18(1):188-97. 96. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2 --a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002; 84:126-34. 97. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92:1472-89. 98. Zhang X, Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 2002 Aug 1; 62(15):4369-75. 99. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-93. 100. Zwart J, Geisler JP, Geisler HE. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol 1998; 19:225-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39336 | - |
dc.description.abstract | 確認哪些訊息傳遞路徑會與腫瘤轉移有關對於了解癌症病理的發生以及對腫瘤轉移機制的研究是非常重要的。腫瘤轉移發生的過程通常牽涉到數個步驟,其中包括增加癌細胞的移動能力、分解細胞外基質以及基底層膜、還有癌細胞的增生。在本篇實驗當中,利用卵巢癌侵襲模型(Ovarian cancer invasion model)來建立卵巢類子宮內膜腺癌細胞株-OVTW59的分株(P0~P4)。它們具有漸進式增強侵襲能力的特性可以用來研究與腫瘤侵襲、轉移相關的基因。藉著互補去氧核糖核酸微矩陣(cDNA microarray)和及時定量聚合酶連鎖反應(Quantitative Real-Time PCR)的幫助,我們可以做整個細胞內基因表現的掃描。並且已找出39個與腫瘤侵襲、轉移相關的基因。隨著卵巢癌細胞侵襲能力增加的時候有13個基因表現被抑制,另外有26個基因表現則是被促進。而在39個與腫瘤侵襲相關的基因之中,從P0進行到P4時,胰島素生長因子結合蛋白-3(IGFBP-3)的基因表現具有極大的差異,這也引起我們的好奇,想要去探討IGFBP-3在卵巢類子宮內膜細胞腺癌中所扮演的角色。為此目的我們首先建立一個能持續表現IGFBP-3的P0和P4的細胞株,把含有人類IGFBP-3基因的載體以及空的載體分別轉植到P0與P4之中,接著再進行下列一連串的實驗。實驗結果發現,IGFBP-3在細胞刮痕的實驗(Scratch Analysis)中能夠抑制癌細胞的移動;在侵襲室能力分析(Invasion Chamber Assay)中,能夠抑制癌細胞侵襲的能力。同時在動物實驗中發現IGFBP-3也能夠抑制腫瘤細胞的生長以及轉移,並且引起腫瘤細胞的凋亡(Apoptosis)以及腫瘤壞死(Tumor Necrosis)。對這些研究的結果,我們試著去探討IGFBP-3在卵巢類子宮內膜細胞腺癌細胞中是如何導致這些現象,以及有哪些訊息傳遞路徑會受到IGFBP-3的影響。研究結果發現IGFBP-3有可能透過抑制ERK-MAPK路徑的活化來達到抑制細胞活動能力(cell mobility)。同時我們也利用ERK路徑的抑制劑-PD98059來驗證,證明IGFBP-3抑制ERK的活化與IGFBP-3使得癌細胞的活動能力降低之間有高度相關。總括來說,本篇實驗發現IGFBP-3的確能夠抑制卵巢類子宮內膜腺癌細胞的移動、侵襲以及轉移的能力,並可誘發癌細胞的凋亡。 | zh_TW |
dc.description.abstract | To identify the signaling pathway responsible for the establishment of a metastatic phenotype in carcinoma cells is of crucial importance for the understanding of the pathogenesis of cancer metastasis. The process of metastasis usually involves several steps, including increase the cell motility to invade, degradation of extracellular matrix and basement membranes and cell proliferation. In our study, we used an ovarian cancer invasion model to define five OVTW59 sublines P0 to P4, with progressive increase in invasion capabilities for investigation of genes involved in invasion and metastasis. By cDNA microarray and quantitative real-time PCR analysis, we performed global gene screening and found 39 genes related with invasion and metastasis. Thirteen genes of them were down-regulated and twenty-six genes were up-regulated with the increase of ovarian cancer invasion. One of the down-regulated invasion-related genes, insulin-like growth factor-binding protein 3 (IGFBP-3), showed surprisingly differential expression in the ovarian cancer invasion model. For investigation of the role of the differentially expressed IGFBP-3 gene in the tumor progression, especially in the invasion and metastasis of ovarian cancer, we transfected a plasmid containing IGFBP-3 cDNA into the P0 and P4 cells. It was found that IGFBP-3 could inhibit cell migration in the scratch analysis and cell invasion in the invasion chamber assay. In addition, it could also inhibit tumor growth and metastasis and induce apoptosis in the animal model. These functions could be reversed when shRNA was transfected. We further studied the inhibitory mechanism of IGFBP-3 in cancer migration, invasion and metastasis, especially focusing in the signaling pathways and the interacting genes related to IGFBP-3. Our result revealed that IGFBP-3 could inhibit the activation of extracellular signal-regulated kinase (ERK)1/2 - mitogen-activated protein kinase (MAPK) signaling pathways. It is concluded that the IGFBP-3 gene, selected from the progressive increase in invasion capability sublines of ovarian cancer cell line, plays a role as a tumor suppressor to inhibit tumor cell migration, invasion and metastasis and to induce apoptosis in ovarian cancer pathogenesis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T17:26:16Z (GMT). No. of bitstreams: 1 ntu-94-R91444005-1.pdf: 4195690 bytes, checksum: 0d1def170fa10de46fe6fb40e403a9f8 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1
Abstract ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 2 Introduction‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥3 Materials and Methods ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 9 Results ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 16 Discussion‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 22 Figures ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 26 Table‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 47 References‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥50 Appendix ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 59 | |
dc.language.iso | en | |
dc.title | IGFBP-3基因表達在卵巢類子宮內膜腺癌中之功能分析 | zh_TW |
dc.title | Functional Analysis of IGFBP-3 Gene Expression in Ovarian Endometrioid Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃奇英,許金玉,林琬琬,吳漢忠 | |
dc.subject.keyword | 卵巢類子宮內膜腺癌, | zh_TW |
dc.subject.keyword | IGFBP-3 ovarian endometrioid carcinoma, | en |
dc.relation.page | 64 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-01-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 4.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。